Alpha adrenergic antagonist: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (New page: In pharmacology, '''alpha adrenergic blockers''' are "drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenerg...) |
imported>Howard C. Berkowitz No edit summary |
||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
In [[pharmacology]], '''alpha adrenergic blockers''' are "drugs that bind to but do not activate alpha-adrenergic | {{subpages}} | ||
In [[pharmacology]], '''alpha adrenergic blockers''' are "drugs that bind to but do not activate alpha-[[adrenergic receptor]]s thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of [[hypertension]], vasospasm, [[peripheral arterial disease|peripheral vascular disease]], [[shock]], and [[pheochromocytoma]]."<ref>{{MeSH}}</ref> They are also used for [[benign prostatic hyperplasia]]. | |||
Naftopidil is more selective for the alpha-1a [[adrenergic receptor]] and has been used to treat [[benign prostatic hyperplasia]].<ref name="pmid19821408">{{cite journal| author=Garimella PS, Fink HA, Macdonald R, Wilt TJ| title=Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. | journal=Cochrane Database Syst Rev | year= 2009 | volume= | issue= 4 | pages= CD007360 | pmid=19821408 | |||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=19821408 | doi=10.1002/14651858.CD007360.pub2 }} </ref> Vascular [[drug toxicity]] may be less with [[tamsulosin]] due to more selectivity to α<sub>1</sub>-A and α<sub>1</sub>-D [[adrenergic receptor]]s according to a [[meta-analysis]] supported by [[Boehringer Ingelheim Pharmaceuticals]], the maker of tamsulosin.<ref name="pmid18822025">{{cite journal| author=Nickel JC, Sander S, Moon TD| title=A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. | journal=Int J Clin Pract | year= 2008 | volume= 62 | issue= 10 | pages= 1547-59 | pmid=18822025 | |||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=18822025 | doi=10.1111/j.1742-1241.2008.01880.x | pmc=PMC2658011 }} </ref> | |||
==Costs== | ==Costs== | ||
According to drugstore.com: | According to drugstore.com: | ||
* [[Alfuzosin]] (Uroxatral) 10 mg - $121.85 for 30 tablets | * [[Alfuzosin]] (Uroxatral) 10 mg - $121.85 for 30 tablets | ||
* [[Doxazosin]] (Cardura) 8 mg - $23.99 for 30 tablets | |||
* [[Naftopidil]] | |||
* [[Prazosin]] (Minipress) 5 mg - $33.99 for ''60'' tablets | |||
* [[Tamsulosin]] (Flomax) 0.4 - $142.19 for 30 tablets | * [[Tamsulosin]] (Flomax) 0.4 - $142.19 for 30 tablets | ||
* [[ | * [[Terazosin]] | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Latest revision as of 11:04, 11 June 2010
In pharmacology, alpha adrenergic blockers are "drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma."[1] They are also used for benign prostatic hyperplasia.
Naftopidil is more selective for the alpha-1a adrenergic receptor and has been used to treat benign prostatic hyperplasia.[2] Vascular drug toxicity may be less with tamsulosin due to more selectivity to α1-A and α1-D adrenergic receptors according to a meta-analysis supported by Boehringer Ingelheim Pharmaceuticals, the maker of tamsulosin.[3]
Costs
According to drugstore.com:
- Alfuzosin (Uroxatral) 10 mg - $121.85 for 30 tablets
- Doxazosin (Cardura) 8 mg - $23.99 for 30 tablets
- Naftopidil
- Prazosin (Minipress) 5 mg - $33.99 for 60 tablets
- Tamsulosin (Flomax) 0.4 - $142.19 for 30 tablets
- Terazosin
References
- ↑ Anonymous (2024), Alpha adrenergic antagonist (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Garimella PS, Fink HA, Macdonald R, Wilt TJ (2009). "Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.". Cochrane Database Syst Rev (4): CD007360. DOI:10.1002/14651858.CD007360.pub2. PMID 19821408. Research Blogging.
- ↑ Nickel JC, Sander S, Moon TD (2008). "A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia.". Int J Clin Pract 62 (10): 1547-59. DOI:10.1111/j.1742-1241.2008.01880.x. PMID 18822025. PMC PMC2658011. Research Blogging.